Atención médica de calidadDescubra por qué Mayo Clinic es el mejor lugar para atenderse. Pide una cita.
Yi Lin, M.D., Ph.D., is a hematologist and oncologist with a clinical practice in lymphoma, multiple myeloma and cell therapy. Dr. Lin also conducts research on cancer, including cancer vaccines and cancer immunotherapy. She has served as a principal investigator on multiple cell therapy clinical trials, including the registration studies that led to approval by the U.S. Food and Drug Administration (FDA) of axicabtagene ciloleucel (Yescarta), idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti). Dr. Lin also has received funding from the National Institutes of Health (NIH) to conduct translational research on novel cancer immunotherapy development and biomarkers of predictors of response and toxicities in immunotherapy.
Cellular immunotherapy has transformed cancer treatment options for patients. However, potential severe side effects that require multidisciplinary care limit access to this treatment for many patients. In addition, there is still opportunity to improve the efficacy of this treatment. Dr. Lin's research aims to better identify tumor and immune characteristics that correlate with severe side effects and resistance to therapy that could be used in real time to facilitate patient risk-adapted management. Using novel bioprint models and gene-editing tools, Dr. Lin is working to develop the next generation of treatment that could be safer and more efficacious.
Infórmate sobre los ensayos clínicos que abordan preguntas científicas específicas sobre la salud humana y las enfermedades.
Ver mis estudios.
Explora todos los estudios de investigación en Mayo Clinic.
Ver las conclusiones revisadas por colegas que publiqué como resultado de mi investigación.